Adrenomedullin as a therapeutic target in angiogenesis

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 10, 2010, Pages 1059-1072

  Deville, Jean Laurent ^a,b   Salas, Sébastien ^a,b   Figarella Branger, Dominique ^a,b   Ouafik, L'Houcine ^a,c   Daniel, Laurent ^a,b  

^a University of the Mediterranean Aix Marseille II   (France)

^b TIMONE HOSPITAL   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE MARSEILLE   (France)

Author keywords

Adrenomedullin; Angiogenesis; Cancer; Therapeutic target

Indexed keywords

ADRENOMEDULLIN; ADRENOMEDULLIN RECEPTOR; ANGIOGENESIS INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; HYPOXIA INDUCIBLE FACTOR 1BETA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY G6; NAKED DNA; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; CANCER CELL CULTURE; CANCER INVASION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM TUMOR; CLEAR CELL CARCINOMA; DRUG TARGETING; HEMATOPOIETIC STEM CELL; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; MORPHOGENESIS; NONHUMAN; PANCREAS CANCER; PROGNOSIS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEINURIA; REVIEW; SOLID TUMOR; TUMOR GROWTH; UPREGULATION;

ADRENOMEDULLIN; ANGIOGENESIS INHIBITORS; ANIMALS; ANOXIA; CELL DIFFERENTIATION; CELL PROLIFERATION; DISEASE PROGRESSION; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MICE; MOLECULAR TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 77957042638     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.2010.522328     Document Type: Review

References (182)

1. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 1993;192(2):553-560 (Pubitemid 23227359)
2. Kitamura K, Sakata J, Kangawa K, et al. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 1993;194(2):720-725
3. Hinson JP, Kapas S, Smith DM. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 2000;21(2):138-167
4. Eguchi S, Hirata Y, Iwasaki H, et al. Structure-activity relationship of adrenomedullin, a novel vasodilatory peptide, in cultured rat vascular smooth muscle cells. Endocrinology 1994;135(6):2454-2458
5. Merkler DJ. C-terminal amidated peptides: production by the in vitro enzymatic amidation of glycine-extended peptides and the importance of the amide to bioactivity. Enzyme Microb Technol 1994;16(6):450-456
6. Caron KM, Smithies O. Extreme hydrops fetalis and cardiovascular abnormalities in mice lacking a functional adrenomedullin gene. Proc Natl Acad Sci USA 2001;98(2):615-619
7. Kapas S, Catt KJ, Clark AJ. Cloning and expression of cDNA encoding a rat adrenomedullin receptor. J Biol Chem 1995;270(43):25344-25347
8. McLatchie LM, Fraser NJ, Main MJ, et al. RAMPs regulate the transport and ligand specificity of the calcitonin-receptor-like receptor. Nature 1998;393(6683):333-339
9. Njuki F, Nicholl CG, Howard A, et al. A new calcitonin-receptor-like sequence in rat pulmonary blood vessels. Clin Sci (Lond) 1993;85(4):385-388
10. Sakata J, Shimokubo T, Kitamura K, et al. Distribution and characterization of immunoreactive rat adrenomedullin in tissue and plasma. FEBS Lett 1994;352(2):105-108
11. Ishiyama Y, Kitamura K, Ichiki Y, et al. Hemodynamic effects of a novel hypotensive peptide, human adrenomedullin, in rats. Eur J Pharmacol 1993;241(2-3):271-273 (Pubitemid 23272891)
12. Rademaker MT, Charles CJ, Lewis LK, et al. Beneficial hemodynamic and renal effects of adrenomedullin in an ovine model of heart failure. Circulation 1997;96(6):1983-1990
13. Ishimitsu T, Nishikimi T, Saito Y, et al. Plasma levels of adrenomedullin, a newly identified hypotensive peptide, in patients with hypertension and renal failure. J Clin Invest 1994;94(5):2158-2161
14. Sumimoto T, Nishikimi T, Mukai M, et al. Plasma adrenomedullin concentrations and cardiac and arterial hypertrophy in hypertension. Hypertension 1997;30(3 Pt 2):741-745
15. Jougasaki M, Wei CM, McKinley LJ, Burnett Jr JC. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 1995;92(3):286-289
16. Nishikimi T, Saito Y, Kitamura K, et al. Increased plasma levels of adrenomedullin in patients with heart failure. J Am Coll Cardiol 1995;26(6):1424-1431
17. Nishikimi T, Nagata S, Sasaki T, et al. Plasma concentrations of adrenomedullin correlate with the extent of pulmonary hypertension in patients with mitral stenosis. Heart 1997;78(4):390-395
18. Yoshibayashi M, Kamiya T, Kitamura K, et al. Plasma levels of adrenomedullin in primary and secondary pulmonary hypertension in patients <20 years of age. Am J Cardiol 1997;79(11):1556-8
19. Kobayashi K, Kitamura K, Hirayama N, et al. Increased plasma adrenomedullin in acute myocardial infarction. Am Heart J 1996;131(4):676-680 (Pubitemid 26119560)
20. Miyao Y, Nishikimi T, Goto Y, et al. Increased plasma adrenomedullin levels in patients with acute myocardial infarction in proportion to the clinical severity. Heart 1998;79(1):39-44
21. Hippenstiel S, Witzenrath M, Schmeck B, et al. Adrenomedullin reduces endothelial hyperpermeability. Circ Res 2002;91(7):618-625
22. Abe M, Sata M, Suzuki E, et al. Effects of adrenomedullin on acute ischaemia-induced collateral development and mobilization of bone-marrow-derived cells. Clin Sci (Lond) 2006;111(6):381-387
23. Iwase T, Nagaya N, Fujii T, et al. Adrenomedullin enhances angiogenic potency of bone marrow transplantation in a rat model of hindlimb ischemia. Circulation 2005;111(3):356-362 (Pubitemid 40165344)
24. Kong XQ, Wang LX, Yang CS, et al. Effects of adrenomedullin on the cell numbers and apoptosis of endothelial progenitor cells. Clin Invest Med 2008;31(3):E117-22
25. Martinez A, Zudaire E, Portal-Nunez S, et al. Proadrenomedullin NH2-terminal 20 peptide is a potent angiogenic factor, and its inhibition results in reduction of tumor growth. Cancer Res 2004;64(18):6489-6494
26. Nikitenko LL, Fox SB, Kehoe S, et al. Adrenomedullin and tumour angiogenesis. Br J Cancer 2006;94(1):1-7
27. Miller MJ, Martinez A, Unsworth EJ, et al. Adrenomedullin expression in human tumor cell lines. Its potential role as an autocrine growth factor. J Biol Chem 1996;271(38):23345-23351
28. Ouafik L, Sauze S, Boudouresque F, et al. Neutralization of adrenomedullin inhibits the growth of human glioblastoma cell lines in vitro and suppresses tumor xenograft growth in vivo. Am J Pathol 2002;160(4):1279-1292
29. Deville JL, Bartoli C, Berenguer C, et al. Expression and role of adrenomedullin in renal tumors and value of its mRNA levels as prognostic factor in clear-cell renal carcinoma. Int J Cancer 2009;125(10):2307-2315
30. Rocchi P, Boudouresque F, Zamora AJ, et al. Expression of adrenomedullin and peptide amidation activity in human prostate cancer and in human prostate cancer cell lines. Cancer Res 2001;61(3):1196-1206
31. Ramachandran V, Arumugam T, Hwang RF, et al. Adrenomedullin is expressed in pancreatic cancer and stimulates cell proliferation and invasion in an autocrine manner via the adrenomedullin receptor, ADMR. Cancer Res 2007;67(6):2666-2675
32. Keleg S, Kayed H, Jiang X, et al. Adrenomedullin is induced by hypoxia and enhances pancreatic cancer cell invasion. Int J Cancer 2007;121(1):21-32 (Pubitemid 46759489)
33. Oehler MK, Fischer DC, Orlowska-Volk M, et al. Tissue and plasma expression of the angiogenic peptide adrenomedullin in breast cancer. Br J Cancer 2003;89(10):1927-1933
34. Buyukberber S, Sari I, Camci C, et al. Adrenomedullin expression does not correlate with survival in lung cancer. Med Oncol 2007;24(2):245-249
35. Liu J, Butzow R, Hyden-Granskog C, Voutilainen R. Expression of adrenomedullin in human ovaries, ovarian sex cord-stromal tumors and cultured granulosa-luteal cells. Gynecol Endocrinol 2009;25(2):96-103
36. Takahashi K, Satoh F, Sone M, et al. Expression of adrenomedullin mRNA in adrenocortical tumors and secretion of adrenomedullin by cultured adrenocortical carcinoma cells. Peptides 1998;19(10):1719-1724
37. Takahashi K, Yoshinoya A, Murakami O, et al. Production and secretion of two vasoactive peptides, adrenomedullin and endothelin-1, by cultured human adrenocortical carcinoma cells. Peptides 2000;21(2):251-256
38. Michelsen J, Thiesson H, Walter S, et al. Tissue expression and plasma levels of adrenomedullin in renal cancer patients. Clin Sci (Lond) 2006;111(1):61-70
39. Ehlenz K, Koch B, Preuss P, et al. High levels of circulating adrenomedullin in severe illness: correlation with C-reactive protein and evidence against the adrenal medulla as site of origin. Exp Clin Endocrinol Diabetes 1997;105(3):156-162
40. Letizia C, Di Iorio R, De Toma G, et al. Circulating adrenomedullin is increased in patients with corticotropin-dependent Cushings syndrome due to pituitary adenoma. Metabolism 2000;49(6):760-763
41. Dupuis J, Caron A, Ruel N. Biodistribution, plasma kinetics and quantification of single-pass pulmonary clearance of adrenomedullin. Clin Sci (Lond) 2005;109(1):97-102
42. Pio R, Martinez A, Unsworth EJ, et al. Complement factor H is a serum-binding protein for adrenomedullin, and the resulting complex modulates the bioactivities of both partners. J Biol Chem 2001;276(15):12292-12300
43. Martinez A, Oh HR, Unsworth EJ, et al. Matrix metalloproteinase-2 cleavage of adrenomedullin produces a vasoconstrictor out of a vasodilator. Biochem J 2004;383(Pt 3):413-418
44. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2(1):38-47
45. Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer 2003;3(10):721-732
46. Huang LE, Gu J, Schau M, Bunn HF. Regulation of hypoxia-inducible factor 1alpha is mediated by an O2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 1998;95(14):7987-7992
47. Salceda S, Caro J. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J Biol Chem 1997;272(36):22642-22647
48. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 1999;399(6733):271-275
49. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet 1994;3(12):2169-2173
50. Gnarra JR, Tory K, Weng Y, et al. Mutations of the VHL tumour suppressor gene in renal carcinoma. Nat Genet 1994;7(1):85-90
51. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma. Proc Natl Acad Sci USA 1994;91(21):9700-9704 (Pubitemid 24311875)
52. Wiesener MS, Munchenhagen PM, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001;61(13):5215-5222
53. Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol 2004;22(24):4991-5004
54. Kuwai T, Kitadai Y, Tanaka S, et al. Mutation of the von Hippel-Lindau (VHL) gene in human colorectal carcinoma: association with cytoplasmic accumulation of hypoxia-inducible factor (HIF)-1alpha. Cancer Sci 2004;95(2):149-153
55. Garayoa M, Martinez A, Lee S, et al. Hypoxia-inducible factor-1 (HIF-1) up-regulates adrenomedullin expression in human tumor cell lines during oxygen deprivation: a possible promotion mechanism of carcinogenesis. Mol Endocrinol 2000;14(6):848-862
56. Nguyen SV, Claycomb WC. Hypoxia regulates the expression of the adrenomedullin and HIF-1 genes in cultured HL-1 cardiomyocytes. Biochem Biophys Res Commun 1999;265(2):382-386
57. Ogita T, Hashimoto E, Yamasaki M, et al. Hypoxic induction of adrenomedullin in cultured human umbilical vein endothelial cells. J Hypertens 2001;19(3 Pt 2):603-608
58. Beyer S, Kristensen MM, Jensen KS, et al. The histone demethylases JMJD1A and JMJD2B are transcriptional targets of hypoxia-inducible factor HIF. J Biol Chem 2008;283(52):36542-36552
59. Pollard PJ, Loenarz C, Mole DR, et al. Regulation of Jumonji-domain- containing histone demethylases by hypoxia-inducible factor (HIF)-1alpha. Biochem J 2008;416(3):387-394
60. Wellmann S, Bettkober M, Zelmer A, et al. Hypoxia upregulates the histone demethylase JMJD1A via HIF-1. Biochem Biophys Res Commun 2008;372(4):892-897
61. Krieg AJ, Rankin EB, Chan D, et al. Regulation of the histone demethylase JMJD1A by hypoxia-inducible factor 1 alpha enhances hypoxic gene expression and tumor growth. Mol Cell Biol 2010;30(1):344-353
62. Michiels C, Minet E, Michel G, et al. HIF-1 and AP-1 cooperate to increase gene expression in hypoxia: role of MAP kinases. IUBMP Life 2001;52(1-2):49-53
63. Minet E, Arnould T, Michel G, et al. ERK activation upon hypoxia: involvement in HIF-1 activation. FEBS Lett 2000;468(1):53-58
64. Zhou J, Fandrey J, Schumann J, et al. NO and TNF- released from activated macrophages stabilize HIF-1 in resting tubular LLC-PK1 cells. Am J Physiol Cell Physiol 2003;284(2):C439-46
65. Jung YJ, Isaacs JS, Lee S, et al. IL-1beta-mediated up-regulation of HIF-1alpha via an NFKappaB/COX-2 pathway identifies HIF-1 as a critical link between inflammation and oncogenesis. FASEB J 2003;17(14):2115-2117
66. Horio T, Nishikimi T, Yoshihara F, et al. Production and secretion of adrenomedullin in cultured rat cardiac myocytes and nonmyocytes: stimulation by interleukin-1beta and tumor necrosis factor-alpha. Endocrinology 1998;139(11):4576-4580
67. Sugo S, Minamino N, Shoji H, et al. Interleukin-1, tumor necrosis factor and lipopolysaccharide additively stimulate production of adrenomedullin in vascular smooth muscle cells. Biochem Biophys Res Commun 1995;207(1):25-32
68. Takahashi K, Nakayama M, Totsune K, et al. Increased secretion of adrenomedullin from cultured human astrocytes by cytokines. J Neurochem 2000;74(1):99-103
69. Gonzalez-Rey E, Chorny A, OValle F, Delgado M. Adrenomedullin protects from experimental arthritis by down-regulating inflammation and Th1 response and inducing regulatory T cells. Am J Pathol 2007;170(1):263-271
70. Miksa M, Wu R, Cui X, et al. Vasoactive hormone adrenomedullin and its binding protein: anti-inflammatory effects by up-regulating peroxisome proliferator-activated receptor-gamma. J Immunol 2007;179(9):6263-6272
71. Ueda S, Nishio K, Minamino N, et al. Increased plasma levels of adrenomedullin in patients with systemic inflammatory response syndrome. Am J Respir Crit Care Med 1999;160(1):132-136
72. Wong LY, Cheung BM, Li YY, Tang F. Adrenomedullin is both proinflammatory and antiinflammatory: its effects on gene expression and secretion of cytokines and macrophage migration inhibitory factor in NR8383 macrophage cell line. Endocrinology 2005;146(3):1321-1327
73. Yang S, Zhou M, Fowler DE, Wang P. Mechanisms of the beneficial effect of adrenomedullin and adrenomedullin-binding protein-1 in sepsis: down-regulation of proinflammatory cytokines. Crit Care Med 2002;30(12):2729-2735
74. OByrne KJ, Dalgleish AG. Chronic immune activation and inflammation as the cause of malignancy. Br J Cancer 2001;85(4):473-483
75. Shacter E, Weitzman SA. Chronic inflammation and cancer. Oncology (Williston Park) 2002;16(2):217-26, 29; discussion 30-32
76. Ishimitsu T, Kojima M, Kangawa K, et al. Genomic structure of human adrenomedullin gene. Biochem Biophys Res Commun 1994;203(1):631-639
77. Imagawa M, Chiu R, Karin M. Transcription factor AP-2 mediates induction by two different signal-transduction pathways: protein kinase C and cAMP. Cell 1987;51(2):251-260
78. Zhang Y, Zhang S, Shang H, et al. Basic fibroblast growth factor upregulates adrenomedullin expression in ovarian epithelial carcinoma cells via JNK-AP-1 pathway. Regul Pept 2009;157(1-3):44-50
79. Casanovas O, Hicklin DJ, Bergers G, Hanahan D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005;8(4):299-309
80. Pearson LJ, Yandle TG, Nicholls MG, Evans JJ. Regulation of endothelin-1 release from human endothelial cells by sex steroids and angiotensin-II. Peptides 2008;29(6):1057-1061
81. Evans JJ, Youssef AH, Yandle TG, et al. Effects of endothelin-1 on release of adrenomedullin and C-type natriuretic peptide from individual human vascular endothelial cells. J Endocrinol 2002;175(1):225-232
82. Dhaun N, Macintyre IM, Melville V, et al. Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease. Hypertension 2009;54(3):e19-20
83. Dhaun N, Macintyre IM, Melville V, et al. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009;54(1):113-119
84. Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109(9):1186-1193
85. Zudaire E, Cuttitta F, Martinez A. Regulation of pancreatic physiology by adrenomedullin and its binding protein. Regul Pept 2003;112(1-3):121-130
86. Patard JJ, Kim HL, Lam JS, et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004;22(16):3316-3322
87. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001;19(6):1649-1657 (Pubitemid 32230864)
88. Park SC, Yoon JH, Lee JH, et al. Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Lett 2008;271(2):314-322
89. Pavel ME, Hoppe S, Papadopoulos T, et al. Adrenomedullin is a novel marker of tumor progression in neuroendocrine carcinomas. Horm Metab Res 2006;38(2):112-118
90. Berenguer C, Boudouresque F, Dussert C, et al. Adrenomedullin, an autocrine/paracrine factor induced by androgen withdrawal, stimulates neuroendocrine phenotype in LNCaP prostate tumor cells. Oncogene 2008;27(4):506-518
91. Krijnen JL, Bogdanowicz JF, Seldenrijk CA, et al. The prognostic value of neuroendocrine differentiation in adenocarcinoma of the prostate in relation to progression of disease after endocrine therapy. J Urol 1997;158(1):171-174
92. Zagars GK, Pollack A, von Eschenbach AC. Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the prostate specific antigen era. Cancer 1997;79(7):1370-1380
93. Hata K, Takebayashi Y, Akiba S, et al. Expression of the adrenomedullin gene in epithelial ovarian cancer. Mol Hum Reprod 2000;6(10):867-872
94. Dotsch J, Harmjanz A, Christiansen H, et al. Gene expression of neuronal nitric oxide synthase and adrenomedullin in human neuroblastoma using real-time PCR. Int J Cancer 2000;88(2):172-175
95. Oehler MK, Norbury C, Hague S, et al. Adrenomedullin inhibits hypoxic cell death by upregulation of Bcl-2 in endometrial cancer cells: a possible promotion mechanism for tumour growth. Oncogene 2001;20(23):2937-2945
96. Nunobiki O, Nakamura M, Taniguchi E, et al. Adrenomedullin, Bcl-2 and microvessel density in normal, hyperplastic and neoplastic endometrium. Pathol Int 2009;59(8):530-536
97. Oehler MK, Hague S, Rees MC, Bicknell R. Adrenomedullin promotes formation of xenografted endometrial tumors by stimulation of autocrine growth and angiogenesis. Oncogene 2002;21(18):2815-2821
98. Martinez A, Vos M, Guedez L, et al. The effects of adrenomedullin overexpression in breast tumor cells. J Natl Cancer Inst 2002;94(16):1226-1237
99. Ishikawa T, Chen J, Wang J, et al. Adrenomedullin antagonist suppresses in vivo growth of human pancreatic cancer cells in SCID mice by suppressing angiogenesis. Oncogene 2003;22(8):1238-1242
100. Ajona D, Castano Z, Garayoa M, et al. Expression of complement factor H by lung cancer cells: effects on the activation of the alternative pathway of complement. Cancer Res 2004;64(17):6310-6318
101. Gasque P, Julen N, Ischenko AM, et al. Expression of complement components of the alternative pathway by glioma cell lines. J Immunol 1992;149(4):1381-1387
102. Gasque P, Thomas A, Fontaine M, Morgan BP. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins. J Neuroimmunol 1996;66(1-2):29-40
103. Junnikkala S, Hakulinen J, Jarva H, et al. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002;87(10):1119-1127
104. Kinders R, Jones T, Root R, et al. Complement factor H or a related protein is a marker for transitional cell cancer of the bladder. Clin Cancer Res 1998;4(10):2511-2520
105. Legoedec J, Gasque P, Jeanne JF, Fontaine M. Expression of the complement alternative pathway by human myoblasts in vitro: biosynthesis of C3, factor B, factor H and factor I. Eur J Immunol 1995;25(12):3460-3466
106. Zudaire E, Martnez A, Garayoa M, et al. Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol 2006;168(1):280-291
107. Guidolin D, Albertin G, Spinazzi R, et al. Adrenomedullin stimulates angiogenic response in cultured human vascular endothelial cells: involvement of the vascular endothelial growth factor receptor 2. Peptides 2008;29(11):2013-2023
108. Levine L, Lucci III JA, Pazdrak B, et al. Bombesin stimulates nuclear factor kappa B activation and expression of proangiogenic factors in prostate cancer cells. Cancer Res 2003;63(13):3495-3502
109. Nikitenko LL, MacKenzie IZ, Rees MC, Bicknell R. Adrenomedullin is an autocrine regulator of endothelial growth in human endometrium. Mol Hum Reprod 2000;6(9):811-819
110. Kato H, Shichiri M, Marumo F, Hirata Y. Adrenomedullin as an autocrine/paracrine apoptosis survival factor for rat endothelial cells. Endocrinology 1997;138(6):2615-2620 (Pubitemid 27215270)
111. Shindo T, Kurihara Y, Nishimatsu H, et al. Vascular abnormalities and elevated blood pressure in mice lacking adrenomedullin gene. Circulation 2001;104(16):1964-1971
112. Fritz-Six KL, Dunworth WP, Li M, Caron KM. Adrenomedullin signaling is necessary for murine lymphatic vascular development. J Clin Invest 2008;118(1):40-50
113. Ichikawa-Shindo Y, Sakurai T, Kamiyoshi A, et al. The GPCR modulator protein RAMP2 is essential for angiogenesis and vascular integrity. J Clin Invest 2008;118(1):29-39
114. Fernandez-Sauze S, Delfino C, Mabrouk K, et al. Effects of adrenomedullin on endothelial cells in the multistep process of angiogenesis: involvement of CRLR/RAMP2 and CRLR/RAMP3 receptors. Int J Cancer 2004;108(6):797-804
115. Kaafarani I, Fernandez-Sauze S, Berenguer C, et al. Targeting adrenomedullin receptors with systemic delivery of neutralizing antibodies inhibits tumor angiogenesis and suppresses growth of human tumor xenografts in mice. FASEB J 2009;23(10):3424-3435
116. Nicoli S, Tobia C, Gualandi L, et al. Calcitonin receptor-like receptor guides arterial differentiation in zebrafish. Blood 2008;111(10):4965-4972
117. Yurugi-Kobayashi T, Itoh H, Schroeder T, et al. Adrenomedullin/cyclic AMP pathway induces Notch activation and differentiation of arterial endothelial cells from vascular progenitors. Arterioscler Thromb Vasc Biol 2006;26(9):1977-1984
118. Gray GE, Mann RS, Mitsiadis E, et al. Human ligands of the Notch receptor. Am J Pathol 1999;154(3):785-794
119. Shutter JR, Scully S, Fan W, et al. Dll4, a novel Notch ligand expressed in arterial endothelium. Genes Dev 2000;14(11):1313-1318
120. Roca C, Adams RH. Regulation of vascular morphogenesis by Notch signaling. Genes Dev 2007;21(20):2511-2524
121. Claxton S, Fruttiger M. Periodic Delta-like 4 expression in developing retinal arteries. Gene Expr Patterns 2004;5(1):123-127
122. Favre CJ, Mancuso M, Maas K, et al. Expression of genes involved in vascular development and angiogenesis in endothelial cells of adult lung. Am J Physiol Heart Circ Physiol 2003;285(5):H1917-38
123. Hofmann JJ, Iruela-Arispe ML. Notch signaling in blood vessels: who is talking to whom about what? Circ Res 2007;100(11):1556-1568
124. Hofmann JJ, Luisa Iruela-Arispe M. Notch expression patterns in the retina: an eye on receptor-ligand distribution during angiogenesis. Gene Expr Patterns 2007;7(4):461-470
125. Villa N, Walker L, Lindsell CE, et al. Vascular expression of Notch pathway receptors and ligands is restricted to arterial vessels. Mech Dev 2001;108(1-2):161-164
126. Hellstrom M, Phng LK, Hofmann JJ, et al. Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis. Nature 2007;445(7129):776-780
127. Leslie JD, Ariza-McNaughton L, Bermange AL, et al. Endothelial signalling by the Notch ligand Delta-like 4 restricts angiogenesis. Development 2007;134(5):839-844
128. Suchting S, Freitas C, le Noble F, et al. The Notch ligand Delta-like 4 negatively regulates endothelial tip cell formation and vessel branching. Proc Natl Acad Sci USA 2007;104(9):3225-3230
129. Carlson TR, Yan Y, Wu X, et al. Endothelial expression of constitutively active Notch4 elicits reversible arteriovenous malformations in adult mice. Proc Natl Acad Sci USA 2005;102(28):9884-9889
130. Kim YH, Hu H, Guevara-Gallardo S, et al. Artery and vein size is balanced by Notch and ephrin B2/EphB4 during angiogenesis. Development 2008;135(22):3755-3764
131. Krebs LT, Shutter JR, Tanigaki K, et al. Haploinsufficient lethality and formation of arteriovenous malformations in Notch pathway mutants. Genes Dev 2004;18(20):2469-2473
132. Trindade A, Kumar SR, Scehnet JS, et al. Overexpression of delta-like 4 induces arterialization and attenuates vessel formation in developing mouse embryos. Blood 2008;112(5):1720-1729
133. Benedito R, Trindade A, Hirashima M, et al. Loss of Notch signalling induced by Dll4 causes arterial calibre reduction by increasing endothelial cell response to angiogenic stimuli. BMC Dev Biol 2008;8:117
134. Hodkinson PS, Elliott PA, Lad Y, et al. Mammalian NOTCH-1 activates beta1 integrins via the small GTPase R-Ras. J Biol Chem 2007;282(39):28991-29001
135. Noguera-Troise I, Daly C, Papadopoulos NJ, et al. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Nature 2006;444(7122):1032-1037
136. Ridgway J, Zhang G, Wu Y, et al. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Nature 2006;444(7122):1083-1087
137. Scehnet JS, Jiang W, Kumar SR, et al. Inhibition of Dll4-mediated signaling induces proliferation of immature vessels and results in poor tissue perfusion. Blood 2007;109(11):4753-4760
138. Kim W, Moon SO, Sung MJ, et al. Angiogenic role of adrenomedullin through activation of Akt, mitogen-activated protein kinase, and focal adhesion kinase in endothelial cells. FASEB J 2003;17(13):1937-1939
139. Shichiri M, Kato H, Doi M, et al. Induction of max by adrenomedullin and calcitonin gene-related peptide antagonizes endothelial apoptosis. Mol Endocrinol 1999;13(8):1353-1363
140. Ouafik L, Berenguer-Daize C, Berthois Y. Adrenomedullin promotes cell cycle transit and up-regulates cyclin D1 protein level in human glioblastoma cells through the activation of c-Jun/JNK/AP-1 signal transduction pathway. Cell Signal 2009;21(4):597-608
141. Albertin G, Sorato E, Oselladore B, et al. Involvement of vascular endothelial growth factor signaling in CLR/RAMP1 and CLR/RAMP2-mediated pro-angiogenic effect of intermedin on human vascular endothelial cells. Int J Mol Med 2010;26(2):289-294
142. Garcia MA, Martin-Santamaria S, de Pascual-Teresa B, et al. Adrenomedullin: a new and promising target for drug discovery. Expert Opin Ther Targets 2006;10(2):303-317
143. Moody TW, Miller MJ, Martinez A, et al. Adrenomedullin binds with high affinity, elevates cyclic AMP, and stimulates c-fos mRNA in C6 glioma cells. Peptides 1997;18(8):1111-1115
144. Ramachandran V, Arumugam T, Langley R, et al. The ADMR receptor mediates the effects of adrenomedullin on pancreatic cancer cells and on cells of the tumor microenvironment. PLoS One 2009;4(10):e7502
145. Miseki T, Kawakami H, Natsuizaka M, et al. Suppression of tumor growth by intra-muscular transfer of naked DNA encoding adrenomedullin antagonist. Cancer Gene Ther 2007;14(1):39-44
146. Tsuchiya K, Hida K, Hida Y, et al. Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization. Int J Oncol 2010;36(6):1379-1386
147. Hida K, Hida Y, Amin DN, et al. Tumor-associated endothelial cells with cytogenetic abnormalities. Cancer Res 2004;64(22):8249-8255
148. Hida K, Hida Y, Shindoh M. Understanding tumor endothelial cell abnormalities to develop ideal anti-angiogenic therapies. Cancer Sci 2008;99(3):459-466
149. Hida K, Klagsbrun M. A new perspective on tumor endothelial cells: unexpected chromosome and centrosome abnormalities. Cancer Res 2005;65(7):2507-2510
150. Izzedine H, Rixe O, Billemont B, et al. Angiogenesis inhibitor therapies: focus on kidney toxicity and hypertension. Am J Kidney Dis 2007;50(2):203-218 (Pubitemid 47095077)
151. Chao J, Chao L. The role of adrenomedullin in cardiovascular and renal function. Drug News Perspect 2002;15(8):511-518
152. Oba S, Hino M, Fujita T. Adrenomedullin protects against oxidative stress-induced podocyte injury as an endogenous antioxidant. Nephrol Dial Transplant 2008;23(2):510-517
153. Dotsch J, Schoof E, Schocklmann HO, et al. Nitric oxide increases adrenomedullin receptor function in rat mesangial cells. Kidney Int 2002;61(5):1707-1713
154. Troughton RW, Lewis LK, Yandle TG, et al. Hemodynamic, hormone, and urinary effects of adrenomedullin infusion in essential hypertension. Hypertension 2000;36(4):588-593
155. Troughton RD, Lainchbury JG, McGregor DO, et al. Adrenomedullin in hypertension. Curr Hypertens Rep 2000;2(1):1-2
156. Nishimatsu H, Hirata Y, Shindo T, et al. Role of endogenous adrenomedullin in the regulation of vascular tone and ischemic renal injury: studies on transgenic/knockout mice of adrenomedullin gene. Circ Res 2002;90(6):657-663
157. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008;8(8):592-603
158. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008;358(19):2039-2049
159. Okazaki T, Ebihara S, Asada M, et al. Granulocyte colony-stimulating factor promotes tumor angiogenesis via increasing circulating endothelial progenitor cells and Gr1+CD11b+ cells in cancer animal models. Int Immunol 2006;18(1):1-9
160. Erber R, Thurnher A, Katsen AD, et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004;18(2):338-340
161. Helfrich I, Scheffrahn I, Bartling S, et al. Resistance to antiangiogenic therapy is directed by vascular phenotype, vessel stabilization, and maturation in malignant melanoma. J Exp Med 2010;207(3):491-503
162. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007;356(2):125-134
163. Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 2007;370(9605):2103-2111
164. Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol 2010;12(5):508-516
165. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356(22):2271-2281 (Pubitemid 46849157)
166. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007;356(2):115-124
167. Rini BI, Halabi S, Rosenberg JE, et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010;28(13):2137-2143
168. Bose D, Meric-Bernstam F, Hofstetter W, et al. Vascular endothelial growth factor targeted therapy in the perioperative setting: implications for patient care. Lancet Oncol 2010;11(4):373-382
169. Eng FC, Easson AM, Szentgyorgyi E, Knox JJ. Sorafenib and surgical complications: a case report of adverse reaction to sorafenib during treatment for renal cell carcinoma. Eur J Surg Oncol 2009;35(2):219-221
170. Scappaticci FA, Fehrenbacher L, Cartwright T, et al. Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J Surg Oncol 2005;91(3):173-180
171. Thomas AA, Rini BI, Stephenson AJ, et al. Surgical resection of renal cell carcinoma after targeted therapy. J Urol 2009;182(3):881-886
172. Murakami S, Nagaya N, Itoh T, et al. Adrenomedullin regenerates alveoli
173. Vadivel A, Abozaid S, van Haaften T, et al. Adrenomedullin promotes lung angiogenesis, alveolar development, and repair. Am J Respir Cell Mol Biol 2010;43(2):152-160
174. Wang H, Tomikawa M, Jones MK, et al. Sequential expression of adrenomedullin and its receptor during gastric ulcer healing in rats. Dig Dis Sci 2000;45(3):591-598
175. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001;7(9):987-989
176. Jain RK. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005;307(5706):58-62
177. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-2342
178. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004;22(11):2184-2191
179. Kabbinavar FF, Hambleton J, Mass RD, et al. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer. J Clin Oncol 2005;23(16):3706-3712
180. Kabbinavar FF, Schulz J, McCleod M, et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005;23(16):3697-3705
181. Jin D, Harada K, Ohnishi S, et al. Adrenomedullin induces lymphangiogenesis and ameliorates secondary lymphoedema. Cardiovasc Res 2008;80(3):339-345
182. Fang C, Miguel MA, Avis I, et al. Non-peptide small molecule regulators of lymphangiogenesis. Lymphat Res Biol 2009;7(4):189-196